CTA Investigational Product Management

Question 1

What is the primary purpose of an Investigational Product (IP) accountability log in clinical trials?

Accepted Answer

To track receipt, dispensing, return, and destruction of all IP at the site

Answer

To record the financial cost of each drug shipment

Answer

To document participant adverse reactions to the study drug

Answer

To schedule upcoming drug shipments from the sponsor

Question 2

According to GCP guidelines, where should investigational products be stored at a clinical trial site?

Accepted Answer

In a designated, secure area under conditions specified by the sponsor protocol

Answer

In any secure location chosen by the principal investigator

Answer

In the same refrigerator used for routine laboratory samples

Answer

In the CTA's office for easy access during participant visits

Question 3

What document typically authorizes the shipment of investigational products to a clinical trial site?

Accepted Answer

The drug shipment authorization or IP release letter from the sponsor

Answer

The site's IRB approval letter

Answer

The executed Clinical Trial Agreement (CTA) contract

Answer

The site initiation visit report

Question 4

Who is typically responsible for dispensing investigational products to study participants at a clinical site?

Accepted Answer

A qualified pharmacist or authorized designee as specified in the protocol

Answer

The Clinical Trial Associate (CTA) assigned to the study

Answer

The sponsor's medical monitor

Answer

The IRB coordinator

Question 5

What is the correct procedure when unused investigational product is returned by a study participant?

Accepted Answer

Document the return in the IP accountability log and quarantine per protocol instructions

Answer

Dispense the returned product to the next enrolled participant immediately

Answer

Discard the product in regular trash to maintain confidentiality

Answer

Ship the returned product back to the sponsor within 24 hours

Question 6

Which regulatory requirement primarily governs the labeling of investigational medicinal products in the United States?

Accepted Answer

21 CFR Part 312 (IND regulations)

Answer

ICH E6 Good Clinical Practice guideline

Answer

ISO 14155 standard for medical device trials

Answer

FDA's Guidance for Industry on Electronic Records

Question 7

What does 'blinding' refer to in the context of investigational product management?

Accepted Answer

The process of withholding treatment assignment from participants and/or site staff to minimize bias

Answer

Removing the lot number from IP packaging to conceal manufacturing data

Answer

Encrypting IP shipment manifests to protect proprietary formulas

Answer

Covering drug labels during participant visits to prevent accidental disclosure